224 terminated. 224 Phase 1, 76 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 224 | Terminated 224 |
| Phase 2 | 76 | Terminated 76 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1 / Phase 2 | Terminated | Servier Bio-Innovation LLC | 13 | 2025-02-25 | 2026-03-30 |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome BMS-986497, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | Bristol-Myers Squibb | 34 | 2024-05-29 | 2026-10-01 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) TQ05105 tablets, TQB3909 tablets - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 21 | 2024-05-13 | 2026-01-05 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine Cladribine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2023-10-09 | 2026-07-30 |
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies BLU-263, Azacitidine - Advanced Systemic Mastocytosis | Phase 1 | Terminated | Blueprint Medicines Corporation | 9 | 2023-09-25 | 2025-04-10 |
| A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms NC525 - Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Terminated | NextCure, Inc. | 28 | 2023-02-28 | 2026-01-28 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia AMG 176, Azacitidine - Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 1 | Terminated | Amgen | 7 | 2022-11-14 | 2025-07-14 |
| A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics AUR103 - Solid Tumor, Adult, Acute Myeloid Leukemia | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 27 | 2022-09-16 | 2026-04-17 |
| TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients TQ05105 Tablets - Myelofibrosis | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 9 | 2022-08-01 | 2025-08-29 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 21 | 2022-03-22 | 2024-01-31 |
| Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML SL-172154, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Shattuck Labs, Inc. | 106 | 2022-03-17 | 2026-03-18 |
| Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Fedratinib Pill - Myeloproliferative Neoplasm | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2022-03-14 | 2025-12-04 |
| Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) MGTA-117 - Acute Myeloid Leukemia, Myelodysplasia | Phase 1 | Terminated | Magenta Therapeutics, Inc. | 22 | 2022-02-14 | 2023-02-09 |
| Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg - Myeloproliferative Neoplasm | Phase 1 | Terminated | Joseph Jurcic | 2 | 2022-01-28 | 2024-04-23 |
| A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes CC-95251, Azacitidine, Venetoclax - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 | Terminated | Bristol-Myers Squibb | 56 | 2022-01-19 | 2025-09-25 |
| A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies DSP107, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Kahr Medical | 25 | 2022-01-13 | 2025-11-10 |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 24 | 2021-12-17 | 2025-11-03 |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS VOR33, Mylotarg - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | Vor Biopharma | 67 | 2021-12-16 | 2025-07-29 |
Showing 20 of 224. Sign in to see all of them.
Myelodysplastic Syndromes (131) · Leukemia, Myeloid, Acute (117) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (54) · Leukemia (48) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (42) · Leukemia, Myelomonocytic, Chronic (32) · Primary Myelofibrosis (30) · Blast Crisis (25) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Myeloproliferative Disorders (25) · Lymphoma, Non-Hodgkin (24) · Multiple Myeloma (24) · Congenital Abnormalities (23) · Lymphoma (20) · Hodgkin Disease (17)
Hemic and Lymphatic Diseases (224) · Hematologic Diseases (221) · Neoplasms by Histologic Type (172) · Neoplasms (170) · Leukemia, Myeloid (152) · Leukemia (119) · Pathologic Processes (107) · Pathological Conditions, Signs and Symptoms (107) · Disease Attributes (106) · Chronic Disease (100) · Immune System Diseases (83) · Immunoproliferative Disorders (79) · Myeloproliferative Disorders (79) · Lymphatic Diseases (78)
Azacitidine (31) · Cytarabine (18) · venetoclax (15) · fludarabine (14) · Cyclophosphamide (13) · fludarabine phosphate (12) · ruxolitinib (11) · Filgrastim (9) · Dasatinib (8) · Whole-Body Irradiation (8) · Alemtuzumab (7) · Busulfan (7) · Decitabine (7) · Granulocyte Colony-Stimulating Factor (7) · Melphalan (7)
M.D. Anderson Cancer Center (20) · National Cancer Institute (NCI) (14) · Incyte Corporation (8) · Masonic Cancer Center, University of Minnesota (8) · Fred Hutchinson Cancer Center (6) · Merck Sharp & Dohme LLC (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Bellicum Pharmaceuticals (4) · Celgene (4) · Novartis Pharmaceuticals (4) · Washington University School of Medicine (4) · Amgen (3) · Astex Pharmaceuticals, Inc. (3) · Baylor College of Medicine (3) · Exelixis (3)
United States (193) · France (18) · Spain (16) · Canada (15) · Italy (14) · United Kingdom (11) · Germany (9) · Australia (8) · Belgium (6) · China (6) · South Korea (6) · Japan (5) · Netherlands (5) · Israel (4) · Norway (3)
Roger Strair, MD, PhD (3) · Adrianna Vlachos, MD (2) · Claudio G. Brunstein, MD, PhD (2) · Farhad Ravandi-Kashani (2) · Farhad Ravandi-Kashani, MD (2) · Fred Zheng, M.D. (2) · Guillermo Garcia-Manero (2)
PMID 31527168, PMID 17151364, PMID 19010875, PMID 19029442, PMID 19139736, PMID 19503090, PMID 20460644, PMID 20563869, PMID 21145590, PMID 22080968, PMID 22987312, PMID 23092873, PMID 23256542, PMID 23393050, PMID 23682558, PMID 24355079, PMID 25824692, PMID 30962222, PMID 33194741, PMID 33197925, PMID 33451977, PMID 34247273, PMID 34951522, PMID 35176457, PMID 36063832, PMID 36841672, PMID 36841758, PMID 36865133, PMID 37290996, PMID 37939122, PMID 38027064, PMID 38871487, PMID 39030997, PMID 39290981, PMID 39821392, PMID 39863139, PMID 39929221, PMID 40198769, PMID 40334082, PMID 40651101, PMID 40752760, PMID 40979071, PMID 41385448, PMID 42013378, PMID 42120728
2017 (5), 2023 (3), P30CA072720 (3), 2016 (2), 2019 (2), N01CM62203 (2), P30CA006973 (2), U01CA076576 (2), UM1CA186644 (2), 2014 (1), 2015 (1), 2018 (1), N01CM00032 (1), N01CM00100 (1), P01CA018029 (1)